ValuationMaybe most posters are frustrated because they have no way of properly evaluating this company. At this time ADK has an idea that is being implemented in limited trials. Even the most enthusiastic predictions have revenue under 20 million. For most healthcare companies that is just a rounding number. Don't expect serious valuation until the revenue is in the hundreds of millions along with actual profits.
Until then ADK is valued like it's peers (LMD , EKG come to mind). I know this is not what you want to hear but you have asked "What's wrong with the share price?.
Alan